Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...

A double-blind, U.S. and Australian Phase IIa trial in 75 patients with Dupuytren’s disease and ≥1 palmar nodule showed that a single injection of Xiaflex significantly reduced mean nodule surface area, consistency score and hardness...

Mid-month SEC filings show Arch Venture Partners has used two companies with roaring stock prices - Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Receptos Inc. (NASDAQ:RCPT) - to completely pay back LPs in its $400 million seventh fund. A...

BioSpecifics Technologies started a double-blind, U.S. Phase II trial of Xiaflex in 20 adult patients with >=2 benign lipomas of similar size. Patients will have 1 lipoma treated with Xiaflex, while the other will receive...

A new tool for in vivo detection of liver toxicity could represent a significant improvement over routine methods that only work in vitro or on tissue slices. 1 The litmus test for the Stanford University...

Top-line data from an open-label, dose-escalation, U.S. Phase II trial in 14 lipoma patients showed that a single injection of Xiaflex met the primary endpoint of actively reducing the visible surface area of the lipoma...

Interim data from 13 evaluable patients with stage IIIc/IV malignant melanoma in the first stage of a 2-stage, open-label, U.S. Phase II trial showed that 10 intratumoral injections of Cavatak produced 3 objective responses defined...

PerkinElmer's Caliper company launched Vectra 2 with AQUA technology in North America, Asia and Europe. Caliper partnered with HistoRx Inc. (New Haven, Conn.) in March to develop the immuno-fluorescence imaging technology to measure proteins in...

PerkinElmer completed its acquisition of fellow life sciences supply company Caliper for $10.50 per share, or about $600 million in cash (see BioCentury, Sept. 12). Caliper Life Sciences Inc. , Hopkinton, Mass.   PerkinElmer Inc. (NYSE:PKI),...